Emerald Investment Advisers LLC Makes New Investment in United Therapeutics Corporation $UTHR

Emerald Investment Advisers LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, HoldingsChannel.com reports. The fund purchased 9,275 shares of the biotechnology company’s stock, valued at approximately $5,025,000.

A number of other institutional investors have also recently made changes to their positions in UTHR. Leuthold Group LLC boosted its stake in United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after purchasing an additional 3,126 shares in the last quarter. UBS Group AG grew its position in United Therapeutics by 45.3% during the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after purchasing an additional 70,445 shares during the last quarter. Nicholas Investment Partners LP increased its stake in United Therapeutics by 478.5% during the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after purchasing an additional 3,766 shares in the last quarter. M&T Bank Corp increased its stake in United Therapeutics by 171.6% during the 4th quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock valued at $1,531,000 after purchasing an additional 1,985 shares in the last quarter. Finally, Seven Fleet Capital Management LP purchased a new position in shares of United Therapeutics in the fourth quarter worth $633,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research note on Thursday, August 6th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Finally, JPMorgan Chase & Co. boosted their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $547.62, for a total transaction of $5,202,390.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,185,729.06. This trade represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,311,581.28. The trade was a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 442,575 shares of company stock valued at $239,326,330 over the last 90 days. 8.60% of the stock is currently owned by insiders.

United Therapeutics Trading Down 1.5%

UTHR opened at $513.12 on Friday. United Therapeutics Corporation has a 12-month low of $302.19 and a 12-month high of $609.35. The firm has a 50 day moving average of $533.08 and a two-hundred day moving average of $537.36. The firm has a market capitalization of $22.01 billion, a PE ratio of 18.36, a P/E/G ratio of 1.76 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned $6.41 EPS. As a group, analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.